AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171

SAN FRANCISCO, Aug. 3, 2026 /PRNewswire/ -- AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a near-commercial Biopharmaceutical company focused on developing targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B (CHB) and other...